Novavax’s stock slides 16% after FDA puts clinical hold on COVID and flu vaccine candidates

By / / Finance / 1 minute of reading



im 292030
Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu vaccine candidates, following a case of motor neuropathy in a participant in a mid-stage trial.



Source link

About The Author

Avatar of Shana Hull
Shana Hull is a professional writer, editor, and interviewer. She's written for a variety of publications in the arts, construction, automotive, travel, real estate, and fashion industries. Shana has also worked as a content strategist for several companies in the finance and technology sectors.

Start typing and press enter to search

Scroll to Top